Details for Patent: 10,456,414

Which drugs does patent 10,456,414 protect, and when does it expire?

Patent 10,456,414 protects HARVONI and is included in two NDAs.

This patent has ninety-eight patent family members in forty-three countries.

Summary for Patent: 10,456,414

Title:	Methods for treating HCV
Abstract:	This invention relates to combinations of therapeutic molecules useful for treating hepatitis C virus infection. The present invention relates to methods, uses, dosing regimens, and compositions.
Inventor(s):	William E. Delaney, IV, John O. Link, Hongmei Mo, David W. Oldach, Adrian S. Ray, William J. Watkins, Cheng Yong Yang
Assignee:	Gilead Sciences Inc
Application Number:	US15/400,088
Patent Claim Types: see list of patent claims	Composition; Dosage form;

error: insufficient information

Drugs Protected by US Patent 10,456,414

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Gilead Sciences Inc	HARVONI	ledipasvir; sofosbuvir	PELLETS;ORAL	212477-001	Aug 28, 2019		RX	Yes	No	10,456,414		Y
Gilead Sciences Inc	HARVONI	ledipasvir; sofosbuvir	PELLETS;ORAL	212477-002	Aug 28, 2019		RX	Yes	Yes	10,456,414		Y
Gilead Sciences Inc	HARVONI	ledipasvir; sofosbuvir	TABLET;ORAL	205834-002	Aug 28, 2019		RX	Yes	No	10,456,414		Y
Gilead Sciences Inc	HARVONI	ledipasvir; sofosbuvir	TABLET;ORAL	205834-001	Oct 10, 2014		RX	Yes	Yes	10,456,414		Y

International Family Members for US Patent 10,456,414

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	088580
Argentina	089578
Australia	2012308295
Australia	2012332827